[{"id":"0c9e63e6-e013-4d60-9884-43f80b3ef7f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04016129","created_at":"2021-01-18T19:43:30.822Z","updated_at":"2024-07-02T16:36:55.506Z","phase":"Phase 1/2","brief_title":"CAR-T Immunotherapy Targeting CD19- ALL","source_id_and_acronym":"NCT04016129","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA","pipe":"","alterations":" ","tags":["CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 12/15/2023","study_completion_date":" 12/15/2023","last_update_posted":"2019-09-19"}]